[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity

Rhea-AI Filing Summary

LeMaitre Vascular, Inc. (LMAT) director Bridget A. Ross reported the acquisition of dividend equivalent rights tied to prior equity awards. On 09/04/2025 Ms. Ross was credited with five separate accruals of dividend equivalent rights that are the economic equivalent of common shares. The accruals total individual amounts of 0.4173, 0.4173, 0.7138, 0.8546, and 0.8697 units and are linked to restricted stock unit and performance share unit awards granted on 12/12/2022, 12/08/2023, and 12/06/2024. Each accrual vests proportionately with the underlying award and carries a reported price of $0 per right. The Form 4 was signed on 09/08/2025.

Positive

• Disclosure filed and signed on 09/08/2025, providing transparency about insider equity accruals
• Accrued dividend equivalent rights are tied to existing RSU/PSU awards and vest proportionately, aligning incentives with shareholders

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Small accruals of dividend equivalent rights were recorded for a director, reflecting routine compensation accounting rather than stock purchases or sales.

The reported items are dividend equivalent rights that accrued on existing restricted stock unit and performance share unit awards granted in 2022, 2023, and 2024. These rights are the economic equivalent of common shares and vest proportionately with the underlying awards, indicating they will convert to value only as those awards vest. Reported amounts per accrual are fractional (under one share each), priced at $0 per right, and thus represent bookkeeping of accrued economic entitlements rather than open-market transactions or option exercises. Impact to share count and dilution is de minimis based on the fractional amounts disclosed.

Compensation Analyst

TL;DR: Disclosure documents routine dividend-equivalent accruals tied to equity compensation; no cash consideration and modest fractional amounts.

The Form 4 lists five separate accrual entries dated 09/04/2025 tied to RSU and PSU grants from 12/12/2022, 12/08/2023, and 12/06/2024. Each entry shows fractional dividend equivalent rights that vest with the underlying awards, reflecting normal executive/director compensation administration. The entries list a price of $0, consistent with dividend equivalents (not purchases). For investors, these entries are routine and not indicative of active buying or selling by the director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ross Bridget A

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	09/04/2025		A		0.4173		(1)	(1)	Common Stock	0.4173	$0	6.5156	D
Dividend Equivalent Rights	(2)	09/04/2025		A		0.4173		(2)	(2)	Common Stock	0.4173	$0	5.5269	D
Dividend Equivalent Rights	(3)	09/04/2025		A		0.7138		(3)	(3)	Common Stock	0.7138	$0	5.3975	D
Dividend Equivalent Rights	(4)	09/04/2025		A		0.8546		(4)	(4)	Common Stock	0.8546	$0	5.8691	D
Dividend Equivalent Rights	(5)	09/04/2025		A		0.8697		(5)	(5)	Common Stock	0.8697	$0	2.9094	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Nathan Ulrich	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Bridget A. Ross report on Form 4 for LMAT?

She reported accruals of five dividend equivalent rights on 09/04/2025 tied to RSU and PSU awards; each right is the economic equivalent of one common share.

How many dividend equivalent rights were accrued and what are the amounts?

Five accruals totaling individual amounts of 0.4173, 0.4173, 0.7138, 0.8546, and 0.8697 dividend equivalent rights were reported.

Are these dividend equivalent rights immediately exercisable or paid?

The Form 4 states these rights vest proportionately with the underlying RSU/PSU awards; they are not shown as exercised or sold and list a price of $0.

Which underlying awards generated these dividend equivalent rights?

They accrued on restricted stock unit awards granted 12/12/2022 and 12/08/2023, performance share units granted 12/12/2022 and 12/08/2023, and an RSU award granted 12/06/2024.

When was the Form 4 signed and filed?

The Form 4 was signed by Nathan Ulrich on 09/08/2025 and reports transactions dated 09/04/2025.